Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

Area of Science:

• Neuroscience
• Psychiatry
• Radiology

Background:

• Depression in Parkinson disease (PD) presents distinct symptoms compared to endogenous depression.
• The exact cause of depression in PD is unknown, but abnormal serotonin neurotransmission is a potential factor.

Purpose of the Study:

• To evaluate in vivo serotonin transporter (5-HTT) availability using PET imaging in individuals with PD who have not used antidepressants.
• To investigate the relationship between depressive symptoms and serotonergic function in PD patients.

Main Methods:

• Thirty-four PD patients and 10 healthy controls underwent clinical assessments, including the Beck Depression Inventory-II (BDI-II) and Hamilton Rating Scale for Depression (HRSD).
• Positron Emission Tomography (PET) with ¹¹C-DASB, a selective serotonin transporter (5-HTT) binding marker, was performed on all participants.

Main Results:

• Depression scores (BDI-II and HRSD) correlated significantly.
• Patients with higher depression scores exhibited increased ¹¹C-DASB binding in the amygdala, hypothalamus, raphe nuclei, and posterior cingulate cortex.
• ¹¹C-DASB binding was decreased in other brain regions for both depressed and non-depressed PD patients compared to controls.

Conclusions:

• Elevated 5-HTT binding in specific brain areas of PD patients with depressive symptoms may indicate reduced extracellular serotonin levels.
• These findings support a significant role for abnormal serotonergic neurotransmission in the pathophysiology of depression associated with Parkinson disease.
• The results suggest that treatments targeting the 5-HTT system may be beneficial for managing depression in PD.